Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Receivables - Other: 2010-2021

Historic Receivables - Other for Myriad Genetics (MYGN) over the last 11 years, with Mar 2021 value amounting to $2.4 million.

  • Myriad Genetics' Receivables - Other fell 4.00% to $2.4 million in Q1 2021 from the same period last year, while for Mar 2021 it was $2.4 million, marking a year-over-year decrease of 4.00%. This contributed to the annual value of $2.0 million for FY2020, which is N/A change from last year.
  • Per Myriad Genetics' latest filing, its Receivables - Other stood at $2.4 million for Q1 2021, which was up 20.00% from $2.0 million recorded in Q4 2020.
  • Over the past 5 years, Myriad Genetics' Receivables - Other peaked at $6.9 million during Q3 2017, and registered a low of $2.0 million during Q3 2020.
  • Over the past 3 years, Myriad Genetics' median Receivables - Other value was $2.9 million (recorded in 2020), while the average stood at $3.2 million.
  • Per our database at Business Quant, Myriad Genetics' Receivables - Other surged by 72.73% in 2017 and then slumped by 58.33% in 2020.
  • Myriad Genetics' Receivables - Other (Quarterly) stood at $6.0 million in 2017, then decreased by 1.67% to $5.9 million in 2018, then crashed by 40.68% to $3.5 million in 2019, then crashed by 42.86% to $2.0 million in 2020, then declined by 4.00% to $2.4 million in 2021.
  • Its last three reported values are $2.4 million in Q1 2021, $2.0 million for Q4 2020, and $2.0 million during Q3 2020.